NZ's Medsafe seeks more info on Janssen Covid-19 vaccine – Expert Reaction
NZ's Medsafe seeks more info on Janssen Covid-19 vaccine – Expert Reaction
This explainer is more than 90 days old. Some of the information might be out of date or no longer relevant. Browse our homepage for up to date content or request information about a specific topic from our team of scientists.
This article has been translated from its original language. Please reach out if you have any feedback on the translation.
New Zealand’s medicines regulator has asked for more information from Janssen, with countries putting the company’s Covid-19 vaccine on hold due to rare blood clot concerns. The Janssen vaccine was next in line to be approved for use in New Zealand, but over the past few days the US, EU, and South Africa have all suspended its use. The SMC asked experts to comment.
New Zealand’s medicines regulator has asked for more information from Janssen, with countries putting the company’s Covid-19 vaccine on hold due to rare blood clot concerns. The Janssen vaccine was next in line to be approved for use in New Zealand, but over the past few days the US, EU, and South Africa have all suspended its use. The SMC asked experts to comment.
Publication
What our experts say
Context and background
Resources
Expert Comments:
Associate Professor James Ussher
I think Medsafe has made the right decision in asking for further information. I note the Americans today have had an emergency meeting on the Janssen vaccine and decided to continue their pause pending further information.
We don’t know yet whether these clots are a rare vaccine related event or whether they’re just a coincidental event, but I think it’s important to thoroughly investigate it, and therefore a pause in usage overseas is entirely appropriate.
It shows that the post-marketing monitoring is an effective and responsive process for detecting and acting upon these rare side-effects and can give people confidence in the monitoring system and that regulators will act upon it. It’s important to note that there have been no reports of similar problems with RNA vaccines from Pfizer (currently used in NZ) or Moderna.
We’re in a fortunate position in New Zealand that we’re not requiring vaccination because we have no circulating virus. So we can safely wait while further information is gathered.
Claire Munro
Out of an abundance of caution, the roll out of the Janssen COVID-19 vaccine has been paused while further information on rare unusual clotting abnormalities can be collected. As of the 12th April 2021, six cases of abnormal clotting were reported to the Vaccine Adverse Event Reporting System (VAERS) in the US. While this is only a small number compared to the ~6.8 million doses administered, it is important all information is appropriately reviewed and this pause gives scientists the opportunity to do so.
In the New Zealand setting, the only vaccine which has been approved for use is the Pfizer-BioNTech COVID-19 vaccine. There have been no reports of this particular clotting concern following 97.9 million doses administered of the Pfizer-BioNTech COVID-19 vaccine. Medsafe will carefully evaluate all the available and emerging data before approval to use can be given.
